Fabio Saponaro1, Andrea Sonaglioni2, Antonio Rossi1, Laura Montefusco1, Michele Lombardo2, Guido Adda1, Maura Arosio3. 1. Unit of Endocrine Diseases and Diabetology, San Giuseppe Hospital, Multimedica IRCCS, Milan, Italy. 2. Unit of Cardiology, San Giuseppe Hospital, Multimedica IRCCS, Milan, Italy. 3. Unit of Endocrine Diseases and Diabetology, San Giuseppe Hospital, Multimedica IRCCS, Milan, Italy; Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy. Electronic address: maura.arosio@unimi.it.
Abstract
AIMS: To investigate whether liraglutide improves diastolic function in type 2 diabetes. METHODS: Thirty-seven patients with type 2 diabetes who began liraglutide therapy between June 2013 and May 2014 were enrolled in this observational, prospective study. 26 patients received liraglutide therapy for at least 6months. The remaining 11 patients withdrew from liraglutide therapy during the first month, were started on other hypoglycaemic therapies and formed the control group. Anthropometric, metabolic and echocardiographic parameters including pulsed wave tissue Doppler imaging were evaluated at baseline and at 6months. RESULTS: In the liraglutide group the early diastolic mitral annulus velocity on the lateral (e-lat) and medial (e-med) sides of the mitral annulus increased from 9.2±3.4 to 11.6±4.7cm/s (p<0.001) and from 6.9±1.7 to 8.4±2.6cm/s (p<0.003), respectively. The ratio of early-to-late velocities on the lateral and medial sides of the mitral annulus increased from 0.7±0.3 to 0.9±0.4 (p<0.001) and from 0.5±0.1 to 0.6±0.1 (p<0.02), respectively. The ratio of early diastolic mitral inflow velocity to early diastolic myocardial relaxation velocity decreased from 10.7±4.3 to 8.5±2.5 (p<0.005). No improvements in diastolic function was detected in the control group. Glucose control improved similarly in both groups: HA1bc -1.5% (-17mmol/mol) vs -1.3% (-14mmol/mol), p=0.67. CONCLUSIONS: In patients with type 2 diabetes, 6months liraglutide treatment was associated with a significant improvement in diastolic function.
AIMS: To investigate whether liraglutide improves diastolic function in type 2 diabetes. METHODS: Thirty-seven patients with type 2 diabetes who began liraglutide therapy between June 2013 and May 2014 were enrolled in this observational, prospective study. 26 patients received liraglutide therapy for at least 6months. The remaining 11 patients withdrew from liraglutide therapy during the first month, were started on other hypoglycaemic therapies and formed the control group. Anthropometric, metabolic and echocardiographic parameters including pulsed wave tissue Doppler imaging were evaluated at baseline and at 6months. RESULTS: In the liraglutide group the early diastolic mitral annulus velocity on the lateral (e-lat) and medial (e-med) sides of the mitral annulus increased from 9.2±3.4 to 11.6±4.7cm/s (p<0.001) and from 6.9±1.7 to 8.4±2.6cm/s (p<0.003), respectively. The ratio of early-to-late velocities on the lateral and medial sides of the mitral annulus increased from 0.7±0.3 to 0.9±0.4 (p<0.001) and from 0.5±0.1 to 0.6±0.1 (p<0.02), respectively. The ratio of early diastolic mitral inflow velocity to early diastolic myocardial relaxation velocity decreased from 10.7±4.3 to 8.5±2.5 (p<0.005). No improvements in diastolic function was detected in the control group. Glucose control improved similarly in both groups: HA1bc -1.5% (-17mmol/mol) vs -1.3% (-14mmol/mol), p=0.67. CONCLUSIONS: In patients with type 2 diabetes, 6months liraglutide treatment was associated with a significant improvement in diastolic function.
Authors: Kieren J Mather; Robert V Considine; LaTonya Hamilton; Niral A Patel; Carla Mathias; Wendy Territo; Adam G Goodwill; Johnathan D Tune; Mark A Green; Gary D Hutchins Journal: J Clin Endocrinol Metab Date: 2018-09-01 Impact factor: 5.958
Authors: Ying-Ying Cai; Shao-Zhou Zou; Cun-Xia Fan; Chun-Yan Wu; Shu Fang; Ping Li; Yao-Ming Xue; Mei-Ping Guan Journal: Nan Fang Yi Ke Da Xue Xue Bao Date: 2018-05-20
Authors: Thomas Nyström; Irene Santos-Pardo; Fredric Hedberg; Johan Wardell; Nils Witt; Yang Cao; Leif Bojö; Bo Nilsson; Johan Jendle Journal: Front Endocrinol (Lausanne) Date: 2017-11-14 Impact factor: 5.555
Authors: Maurice B Bizino; Ingrid M Jazet; Jos J M Westenberg; Huub J van Eyk; Elisabeth H M Paiman; Jan W A Smit; Hildebrandus J Lamb Journal: Cardiovasc Diabetol Date: 2019-04-30 Impact factor: 9.951